215-987-2019

Mesothelioma Clinical Trials

Mesothelioma Clinical TrialsHere is a listing of the current Mesothelioma Clinical Trials from the National Cancer Institute:

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-GFPC-ELCWP-0701, NCT00651456

Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2005_010, MK0683-014, NCT00128102

Phase III Randomized Study of an Electronic Tool for Monitoring Symptoms and Syndromes Associated With Advanced Cancer (E-MOSAIC) in Patients With Advanced Incurable Cancer Receiving Palliative Anticancer Treatment
Phase: Phase III
Type: Health services research
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-95/06, SAKK-95/06, EU-20711, SWS-SAKK-E-MOSAIC, NCT00477919

Phase III Randomized Study of Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Who are Opioid Tolerant
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-05-001, INS-05-001, NCT00538850, NCT00538850

Phase III Study of Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Who are Opioid Tolerant
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-06-007, INS-06-007, NCT00538863

Phase III Randomized Study of Video-Assisted Thoracoscopic Cytoreductive Pleurectomy Versus Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PAPWORTH-MESOVATS, MESOVATS, PAPWORTH-P00804, EU-20901, ISRCTN34321019, NCT00821860

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NGR015, 2009-016879-29, NCT01098266

Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBP08-01, NCT00700336

Multiple Respiration-Correlated Cone Beam Computed Tomography (CT) Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer
Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 08-080, NCT00722605

Short Neoadjuvant Hemithoracic IMRT for MPM
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-0106-C, NCT00797719

Phase I/II Randomized Study of Pemetrexed Disodium and Cisplatin With Versus Without Cediranib Maleate in Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0905, S0905, NCT01064648

Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
Phase: Phase II
Type: Diagnostic
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: SP-14-0038, NCT00123773

Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04-063, NCT00165503

Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-14203B, NCI-7103, 7103, NCT00309946

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF3442S, NCT00295503

Phase II Randomized Study of Neoadjuvant Therapy With Pemetrexed Disodium and Cisplatin Followed By Extrapleural Pneumonectomy With or Without Postoperative Hemithoracic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: SWS-SAKK-17/04, EU-20615, EUDRACT-2006-000445-19, LILLY-SAKK-17/04, NCT00334594

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Phase: Phase II

Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ONC-2006-003, EUDRACT 2006-004429-27, NCT00407459

Phase II Study of Bortezomib and Cisplatin as First-Line Treatment in Patients With Malignant Mesothelioma
Phase: Phase II

Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: EORTC-08052, JJPRD-26866138CAN2012, EUDRACT-2006-000009-51, 08052, NCT00458913

Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
Phase: Phase II

Type: Treatment
Status: Active
Age: 20 to 70
Sponsor: Other
Protocol IDs: WUCC-0701, NCT00454519

Tomotherapy Treatment for Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LU-11-0077, NCT00469196

Phase II Study of Bortezomib in Patients With Malignant Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICORG-05-10, ICORG-05-10, EUDRACT-2005-004420-39, EU-20748, NCT00513877

Phase II Study of Pemetrexed Disodium, Cisplatin, and Vitamin B12 in Patients With Unresectable Pleural Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: COL-ALIMESO, ALIMESO, INCA-RECF0441, COL-2006-04, NCT00541073

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GIMe/01/06, NCT00551252

An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TL139204, NCT00685204

Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-053, NCT00715611

New Clinical Trials for Mesothelioma Patients

The Dana-Farber Cancer Institute at Brigham and Women’s Hospital in Boston is currently searching for mesothelioma patients to take part in a clinical trial that will study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. This Phase I trial will also research the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.

The study, which will be completed in 2010, will also involve the surgical procedure known as extrapleural pneumonectomy or pleurectomy/decortication, which includes the resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm). The chemotherapy drugs will be administered immediately following the surgery.
 

Last updated by at .